280 related articles for article (PubMed ID: 34823002)
1. Stromal disruption facilitating invasion of a 'nano-arsenal' into the solid tumor.
Fu Y; Saraswat AL; Monpara J; Patel K
Drug Discov Today; 2022 Apr; 27(4):1132-1141. PubMed ID: 34823002
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine Strategies to Circumvent Intratumor Extracellular Matrix Barriers for Cancer Therapy.
Xu X; Wu Y; Qian X; Wang Y; Wang J; Li J; Li Y; Zhang Z
Adv Healthc Mater; 2022 Jan; 11(1):e2101428. PubMed ID: 34706400
[TBL] [Abstract][Full Text] [Related]
3. Tumor microenvironment and nanotherapeutics: intruding the tumor fort.
Ravi Kiran AVVV; Kusuma Kumari G; Krishnamurthy PT; Khaydarov RR
Biomater Sci; 2021 Nov; 9(23):7667-7704. PubMed ID: 34673853
[TBL] [Abstract][Full Text] [Related]
4. Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors.
Kim J; Cho H; Lim DK; Joo MK; Kim K
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373227
[TBL] [Abstract][Full Text] [Related]
5. Effect of biophysical properties of tumor extracellular matrix on intratumoral fate of nanoparticles: Implications on the design of nanomedicine.
Tian Y; Cheng T; Sun F; Zhou Y; Yuan C; Guo Z; Wang Z
Adv Colloid Interface Sci; 2024 Apr; 326():103124. PubMed ID: 38461766
[TBL] [Abstract][Full Text] [Related]
6. Vascular and extracellular matrix remodeling by physical approaches to improve drug delivery at the tumor site.
Gouarderes S; Mingotaud AF; Vicendo P; Gibot L
Expert Opin Drug Deliv; 2020 Dec; 17(12):1703-1726. PubMed ID: 32838565
[TBL] [Abstract][Full Text] [Related]
7. Modulating the tumor microenvironment with new therapeutic nanoparticles: A promising paradigm for tumor treatment.
Zhang Y; Ho SH; Li B; Nie G; Li S
Med Res Rev; 2020 May; 40(3):1084-1102. PubMed ID: 31709590
[TBL] [Abstract][Full Text] [Related]
8. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier F
J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
[TBL] [Abstract][Full Text] [Related]
9. Strategies to improve tumor penetration of nanomedicines through nanoparticle design.
Zhang YR; Lin R; Li HJ; He WL; Du JZ; Wang J
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1519. PubMed ID: 29659166
[TBL] [Abstract][Full Text] [Related]
10. Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment.
Tanaka HY; Kano MR
Cancer Sci; 2018 Jul; 109(7):2085-2092. PubMed ID: 29737600
[TBL] [Abstract][Full Text] [Related]
11. Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment.
Park J; Choi Y; Chang H; Um W; Ryu JH; Kwon IC
Theranostics; 2019; 9(26):8073-8090. PubMed ID: 31754382
[TBL] [Abstract][Full Text] [Related]
12. Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles.
Niu Y; Zhu J; Li Y; Shi H; Gong Y; Li R; Huo Q; Ma T; Liu Y
J Control Release; 2018 May; 277():35-47. PubMed ID: 29545106
[TBL] [Abstract][Full Text] [Related]
13. Emerging strategies against tumor-associated fibroblast for improved the penetration of nanoparticle into desmoplastic tumor.
Yunna C; Mengru H; Fengling W; Lei W; Weidong C
Eur J Pharm Biopharm; 2021 Aug; 165():75-83. PubMed ID: 33991610
[TBL] [Abstract][Full Text] [Related]
14. Human solid tumors and clinical relevance of the enhanced permeation and retention effect: a 'golden gate' for nanomedicine in preclinical studies?
Gawali P; Saraswat A; Bhide S; Gupta S; Patel K
Nanomedicine (Lond); 2023 Jan; 18(2):169-190. PubMed ID: 37042320
[TBL] [Abstract][Full Text] [Related]
15. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
Shi Y; van der Meel R; Chen X; Lammers T
Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
[TBL] [Abstract][Full Text] [Related]
16. Remodeling the Tumor Microenvironment with Emerging Nanotherapeutics.
Chen Q; Liu G; Liu S; Su H; Wang Y; Li J; Luo C
Trends Pharmacol Sci; 2018 Jan; 39(1):59-74. PubMed ID: 29153879
[TBL] [Abstract][Full Text] [Related]
17. Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors.
Miao L; Lin CM; Huang L
J Control Release; 2015 Dec; 219():192-204. PubMed ID: 26277065
[TBL] [Abstract][Full Text] [Related]
18. Physical oncology: New targets for nanomedicine.
Nicolas-Boluda A; Silva AKA; Fournel S; Gazeau F
Biomaterials; 2018 Jan; 150():87-99. PubMed ID: 29035739
[TBL] [Abstract][Full Text] [Related]
19. Tumor microenvironment remodeling-based penetration strategies to amplify nanodrug accessibility to tumor parenchyma.
Liu Y; Zhou J; Li Q; Li L; Jia Y; Geng F; Zhou J; Yin T
Adv Drug Deliv Rev; 2021 May; 172():80-103. PubMed ID: 33705874
[TBL] [Abstract][Full Text] [Related]
20. Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors.
Han X; Xu Y; Geranpayehvaghei M; Anderson GJ; Li Y; Nie G
Biomaterials; 2020 Feb; 232():119745. PubMed ID: 31918228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
